CoreCap Advisors LLC Sells 104 Shares of Eli Lilly and Company (NYSE:LLY)

CoreCap Advisors LLC lowered its position in Eli Lilly and Company (NYSE:LLYGet Rating) by 4.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,363 shares of the company’s stock after selling 104 shares during the period. CoreCap Advisors LLC’s holdings in Eli Lilly and were worth $766,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LLY. Cordant Inc. bought a new position in shares of Eli Lilly and in the first quarter valued at approximately $25,000. Castle Wealth Management LLC bought a new position in shares of Eli Lilly and in the second quarter valued at approximately $28,000. Horan Securities Inc. lifted its holdings in shares of Eli Lilly and by 96.0% in the second quarter. Horan Securities Inc. now owns 98 shares of the company’s stock valued at $32,000 after purchasing an additional 48 shares in the last quarter. Cypress Capital Management LLC WY increased its position in shares of Eli Lilly and by 300.0% during the second quarter. Cypress Capital Management LLC WY now owns 100 shares of the company’s stock valued at $32,000 after acquiring an additional 75 shares during the last quarter. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Eli Lilly and during the first quarter valued at approximately $33,000. Institutional investors own 82.45% of the company’s stock.

Eli Lilly and Price Performance

Shares of NYSE LLY opened at $361.67 on Monday. The stock has a market cap of $343.65 billion, a PE ratio of 54.30, a price-to-earnings-growth ratio of 2.28 and a beta of 0.36. Eli Lilly and Company has a fifty-two week low of $231.87 and a fifty-two week high of $369.80. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.88 and a current ratio of 1.13. The stock has a fifty day moving average of $335.81 and a 200-day moving average of $320.01.

Eli Lilly and Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be given a $0.98 dividend. This represents a $3.92 annualized dividend and a dividend yield of 1.08%. The ex-dividend date of this dividend is Monday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 58.86%.

Insider Activity at Eli Lilly and

In related news, major shareholder Lilly Endowment Inc sold 161,936 shares of Eli Lilly and stock in a transaction on Friday, October 21st. The stock was sold at an average price of $338.32, for a total transaction of $54,786,187.52. Following the completion of the sale, the insider now owns 103,363,810 shares of the company’s stock, valued at $34,970,044,199.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Alonzo Weems sold 656 shares of Eli Lilly and stock in a transaction on Monday, October 10th. The stock was sold at an average price of $326.23, for a total transaction of $214,006.88. Following the completion of the sale, the executive vice president now owns 6,950 shares of the company’s stock, valued at $2,267,298.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 161,936 shares of Eli Lilly and stock in a transaction on Friday, October 21st. The shares were sold at an average price of $338.32, for a total value of $54,786,187.52. Following the sale, the insider now directly owns 103,363,810 shares of the company’s stock, valued at approximately $34,970,044,199.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 571,297 shares of company stock valued at $193,929,777. Company insiders own 0.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on LLY shares. The Goldman Sachs Group increased their price target on Eli Lilly and from $281.00 to $313.00 and gave the company a “neutral” rating in a research report on Tuesday, November 8th. Barclays increased their price target on Eli Lilly and from $355.00 to $395.00 and gave the company an “overweight” rating in a research report on Wednesday, November 2nd. UBS Group raised Eli Lilly and from a “neutral” rating to a “buy” rating and increased their price target for the company from $335.00 to $363.00 in a research report on Thursday, September 22nd. Citigroup increased their price target on Eli Lilly and from $285.00 to $370.00 in a research report on Thursday, August 25th. Finally, Truist Financial raised their target price on Eli Lilly and from $400.00 to $421.00 in a research report on Tuesday, November 15th. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $355.89.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.